Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting learning session on understanding the best treatment approaches of ALK positive lung cancer.
In this webinar, a panel discussion would take place involving Dr. Todd Bauer as the primary speaker and Dr. Ullas Batra as a moderator who will share the important facts associated with treatment approaches for management of ALK positive lung cancer.
Dr. Todd Bauer has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, a discussion on all possible treatment approaches and their pros, cons are discussed.
ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.
Therefore, you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Mapping lifelong chronic health risks for childhood cancer survivors
2.
High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?
3.
Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs
4.
Coffee, Tea Tied to Lower Risk of Head and Neck Cancer
5.
MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC
1.
Target-Mediated Drug Disposition in Hematologic Therapeutics
2.
Unlocking the Potential of Polatuzumab for Cancer Treatment
3.
Unlocking the Unknown: A Comprehensive Guide to Stage 4 Vulvar Cancer
4.
An Overview Of Leukemia Cutis: What It Is And How To Treat It
5.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
5.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation